Neurogene Inc. — Director's Dealing 2023

Jun 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2023-06-08

Reporting Person: SIMPSON TODD E (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-08	Stock Option (Right to Buy)	$0.79	A	25000	Acquired	2033-06-07	Common Stock (25000)	Direct

Footnotes

F1: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.